EP1530466A2 - Use of lck inhibitor for treatment of immunologic diseases - Google Patents

Use of lck inhibitor for treatment of immunologic diseases

Info

Publication number
EP1530466A2
EP1530466A2 EP03792292A EP03792292A EP1530466A2 EP 1530466 A2 EP1530466 A2 EP 1530466A2 EP 03792292 A EP03792292 A EP 03792292A EP 03792292 A EP03792292 A EP 03792292A EP 1530466 A2 EP1530466 A2 EP 1530466A2
Authority
EP
European Patent Office
Prior art keywords
phenyl
indolinone
phenylamino
methylene
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03792292A
Other languages
German (de)
French (fr)
Other versions
EP1530466B1 (en
Inventor
Gerald Jürgen Roth
Rudolf Hauptmann
Frank Hilberg
Florian Colbatzky
Steffen Ernst
Armin Heckel
Martin Friedrich Stefanic
Rainer Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to SI200332413T priority Critical patent/SI1530466T1/en
Priority to EP10184940A priority patent/EP2281561A3/en
Publication of EP1530466A2 publication Critical patent/EP1530466A2/en
Application granted granted Critical
Publication of EP1530466B1 publication Critical patent/EP1530466B1/en
Priority to CY20151100238T priority patent/CY1116093T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using a compound selected from compounds (A) to (AL) listed below already known as kinase inhibitors for therapy in oncology, and the use of these compounds for the manufacture of a pharmaceutical composition for the treatment of said immunologic diseases or pathological conditions.
  • TCR T-cell antigen receptor
  • Part 1 Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J. Allergy Clin Immunol, 109, 5, 758-770, 2002) and possibly T-cell survival (Seddon, B.; Legname, G.; Tomlinson, P.; Zamoyska, R.
  • a Lck inhibitor has a high possible therapeutic potential in the treatment of T-cell mediated diseases, e.g. in the treatment of immunologic diseases.
  • Certain autoimmune diseases such as inflammatory diseases (for example inflammatory bowel disease, rheumatoid arthritis, glomerulonephritis and lung fibrosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma, multiple sclerosis and type 1 diabetes are believed to be associated with inappropriate T cell activation (J. H. Hanke et al., Inflamm. Res., 1995, 357).
  • Lck inhibitors offer an approach for treatment of the indications mentioned hereinbefore. Agents of this kind would offer therapy for transplant rejection and autoimmune diseases whilst avoiding toxicities associated with the commonly used, less selective immunosuppressants.
  • the leading agent for prevention or treatment of transplant rejection is cyclosporin A which, although effective, is often associated with side-effects such as renal damage and hypertension which results in kidney failure in a substantial number of patients.
  • a second object of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound selected from compounds (A) to (AL) together with one or more other drugs selected from nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs), immunsuppressives, biologic response modifiers and antinfectives for use in treatment of immunologic diseases or pathological conditions involving an immunologic component.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • steroids steroids
  • DMARDs disease-modifying antirheumatic drugs
  • immunsuppressives biologic response modifiers and antinfectives for use in treatment of immunologic diseases or pathological conditions involving an immunologic component.
  • a third object of the invention is the use of a compound selected from compounds (A) to (AL) for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
  • V (Z)-3-(1 -(4-(pyrrolidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
  • W (Z)-3-(1 -(4-(diethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
  • the present invention provides a method for treating immunologic diseases or pathological conditions involving an immunologic component comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising a compound selected from compounds (A) to (AL), the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.
  • patient is meant to comprise the human and the non-human mammal patient.
  • immunologic diseases or pathological conditions involving an immunologic component should be understood in a non-limiting manner to comprise
  • autoimmune diseases for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from
  • inflammatory bowel disease e.g. colitis ulcerosa and Morbus Crohn
  • rheumatoid arthritis e.g. rheumatoid arthritis
  • glomerulonephritis e.g. glomerulonephritis and lung fibrosis
  • psoriasis psoriasis arthritis
  • hypersensitivity reactions of the skin atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes
  • tissue or organ transplant rejection e.g. acute or chronic graft-versus-host disease, allograft or xenograft rejection etc.
  • the transplanted organ may be kidney, heart, liver, lung, bone marrow, peripheral blood stem cells, pancreas or islet cells thereof, cornea, small bowel, skin, or heart valve.
  • inflammatory bowel disease such as colitis ulcerosa and Morbus Crohn, psoriasis, psoriasis arthritis,
  • tissue or organ transplant rejection acute or chronic graft-versus-host disease, allograft or xenograft rejection,
  • a further subgroup of indications which may be treated by the method according to the invention and deserves special mention comprises morbus crohn, lung fibrosis, psoriasis arthritis, hypersensitivity reactions of the skin, graft-versus-host disease (acute and chronic), asthma, multiple sclerosis and type 1 diabetes.
  • the tautomers, the stereoisomers and the physiologically acceptable salts thereof optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.
  • Another preferred embodiment of the method according to the invention comprises administration of a compound selected from the following combined inhibitors of VEGFR-2 and Lck
  • VEGF also plays an important pathogenetical role in chronic inflammatory bowel diseases such as colitis ulcerosa and morbus crohn as well as in rheumatoid arthritis, psoriasis and psoriasis arthritis
  • these combined inhibitors of VEGFR-2 and Lck are of special advantage in these most preferred indications.
  • compounds (A) to (AL) can be administered orally, parenterally, rectally or, with respect to indications involving treatment of the skin such as psoriasis, psoriasis arthritis or hypersensitivity reactions of the skin, also in topical formulations. Oral administration is preferred.
  • the compounds may be given, if required in divided doses, in a daily dosage of 0.1 to 20 mg/kg body weight, preferably 0.5 to 20 mg/kg body weight, most preferred 1 to 10 mg/kg body weight.
  • a daily dosage of 0.1 to 20 mg/kg body weight preferably 0.5 to 20 mg/kg body weight, most preferred 1 to 10 mg/kg body weight.
  • the compounds may be administered in lower doses, for instance in a total daily dosage of 0.01 to 5 mg/kg body weight, preferably 0.05 to 2 mg/kg body weight, most preferred 0.1 to 1 mg/kg body weight.
  • the compounds may be formulated with one or more conventional inert carriers and/or diluents as known in the art, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, lozenges, hard or soft capsules, dispersible powders or granules, syrups or elixirs, injectable solutions, ampoules, aqueous or oily suspensions, emulsions, solutions, sprays, creams, ointments, gels, or suppositories.
  • suitable galenic formulations are disclosed in the documents cited hereinbefore.
  • a compound selected from compounds (A) to (AL) may be administered in combination, simultaneously or sequentially, with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers, antinfectives and, in case of lung indications, also with bronchodilators.
  • one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers, antinfectives and, in case of lung indications, also with bronchodilators.
  • a compound selected from compounds (A) to (AL) could be used in combination with immunosuppressives in the prevention or treatment of the acute rejection of transplanted organs,
  • NSAID-dose in combination with NSAIDs, steroids, immunosupressives, DMARDs, biologic response modifiers (e.g. Anti-TNF), and antiinfectives for the treatment of inflammatory bowel disease (e.g. colitis ulcerosa and morbus crohn), rheumatoid arthritis and psoriasis, whereby the NSAID-dose can be significantly reduced compared to the normally needed dose to produce a therapeutic effect thus reducing the risk of adverse side-effects from the NSAID such as gastrointestinal effects,
  • biologic response modifiers e.g. leukotriene antagonists
  • bronchodilators for the treatment of asthma
  • Suitable NSAIDs for combination treatment are meant to include all COX (cyclooxygenase) inhibitors, e.g.
  • non-selective COX-inhibitors such as acetylsalicyclic acid, mesalazin, ibuprofen, naproxen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen,
  • non-selective COX-inhibitors such as acetylsalicyclic acid, mesalazin, ibuprofen, naproxen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen
  • indomethacin sulindac, tolmetin, zomepirac, nabumetone, diclofenac, fenclofenac, alclofenac, bromfenac, ibufenac, aceclofenac, acemetacin, fentiazac, clidanac, etodolac, oxpinac,
  • mefenamic acid meclofenamic acid, flufenamic acid, nifluminic acid, tolfenamic acid, diflunisal, flufenisal, piroxicam, tenoxicam, lornoxicam and nimesulide and the pharmaceutically acceptable salts thereof,
  • COX 2-inhibitors such as meloxicam, celecoxib and rofecoxib and the pharmaceutically acceptable salts thereof.
  • Suitable steroids for combination treatment are meant to include in a non-limiting manner prednisone, prednisolone, methylprednisolone, dexamethasone, budenoside, fluocortolone and triamcinolone.
  • Suitable DMARDs for combination treatment are meant to include in a non-limiting manner sulfasalazine, olsalazine, chloroquin, gold derivatives (Auranofin), D- penicillamine and cytostatics such as methotrexate and cyclophosphamide.
  • Suitable immunsuppressives for combination treatment are meant to include in a non-limiting manner cyclosporin A and derivatives thereof, mycophenolatemofetil, FK 506, OKT-3, ATG, 15-desoxyspergualin, mizoribine, misoprostol, rapamycin, reflunomide, azathioprine and NF-Kappa B-inhibitors.
  • Suitable biologic response modifiers for combination treatment are meant to include in a non-limiting manner interferon beta, anti-TNF-alpha (Etanercept), IL-10, oral and parenteral tolerance induction strategies (orally e.g. with genetically modified enteric bacteria), leukotrien-antagonists, anti-CD3 or anti-CD25.
  • Suitable antinfectives for combination treatment are meant to include in a non-limiting manner metronidazol and chinolone for treatment of chronic inflammatory bowel diseases.
  • Suitable bronchodilators for combination treatment are meant to include in a non- limiting manner those disclosed under "broncholytics/antiasthmatics" in Rote Liste ® 2002, Editio Cantor Verlag Aulendorf, Germany, being herewith incorporated by reference, for instance ipratropiumbromide, oxytropiumbromide, tiotropiumbromide, epinephrinehydrochloride, salbutamole, terbutalinsulfate, fenoterolhydrobromide, salmeterole, formoterole, cromiclinic acid, theophylline derivatives etc.
  • each active ingredient can be administered either in accordance with its usual dosage range or a dose below its usual dosage range.
  • the dosage for the combined NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives is appropriately 1/50 of the lowest dose normally recommended up to 1/1 of the normally recommended dosage, preferably 1/20 to 1/2 and more preferably 1/10 to 1/5.
  • the normally recommended dose for the combined drug should be understood to be the dose disclosed for example in Rote Liste ® 2002, Editio Cantor Verlag Aulendorf, Germany, or in Physician's Desk Reference.
  • combination treatment comprising administration of Lck inhibitors together with a second drug selected from those mentioned hereinbefore may provide synergistic efficacy thus allowing significant dose reduction compared to the normally needed dose to produce a therapeutic effect. This would be especially beneficial with regard to medications having a high risk of adverse side-effects as is the case with non-selective COX inhibitors, cyclosporin A or DMARDs.
  • the present invention also relates to pharmaceutical composition
  • compositions (a) and (b) optionally together with pharmaceutically acceptable diluents and/or carriers, as a combined preparation or a kit of parts containing components (a) and (b) in separate containments for simultaneous, separate or sequential use in treatment of immunologic diseases or pathological conditions involving an immunologic component.
  • the present invention provides the use of a compound selected from compounds (A) to (AL), the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, for the manufacture of a pharmaceutical composition for the treatment of a patient suffering from immunologic diseases or pathological conditions involving an immunologic component.
  • drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives
  • composition aspect or the use aspect of the invention with respect to the combined VEGFR-2/Lck component correspond to those mentioned hereinbefore for the method of treatment aspect.
  • the lck enzyme comprises the entire lck molecule except the first nine amino acids which are replaced by an His-tag for purification purposes.
  • the enzyme is affinity purified.
  • the well is washed three times with 1x Delfia wash buffer (Wallac, 1244-114, 25x concentrate, diluted with water) and finally 100 ⁇ l Delfia enhancement solution (Wallac, 1244-105) are added.
  • Time resolved fluorescense is measured in a Wallac Victor2 1420 Multilabel Counter, excitation is at 340 nm, emission is measured at 615 nm (delay time 400 ⁇ sec, wi ndow ti me 1000 ⁇ sec) .

Abstract

The invention relates to a method of treating immunologc diseases or pathological conditions involving an immunologc component using Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressive, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said LcK inhibitoir together with said other drugs, and the use of LcK inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.

Description

Use of Lck inhibitors for treatment of immunologic diseases
TECHNICAL FIELD OF THE INVENTION
This invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using a compound selected from compounds (A) to (AL) listed below already known as kinase inhibitors for therapy in oncology, and the use of these compounds for the manufacture of a pharmaceutical composition for the treatment of said immunologic diseases or pathological conditions.
BACKGROUND OF THE INVENTION
Compounds (A) to (AL) listed below, their preparation as well as the pharmacological activity of these compounds based on inhibition of kinases, e.g. VEGFR-2, suitable for therapy in oncology, are disclosed in WO 02/36564, WO 99/52869, WO 00/18734, WO 00/73297, WO 01/27080, WO 01/27081 and WO 01/32651. The cited documents are herewith incorporated by reference with respect to any aspects disclosed relating to these specific compounds.
Lck, a further tyrosine kinase belonging to the src family of tyrosine kinases not mentioned in the references cited above, is functionally required for T-cell activation through the T-cell antigen receptor (TCR) (see A.E. Nel: T-cell activation through antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J. Allergy Clin Immunol, 109, 5, 758-770, 2002) and possibly T-cell survival (Seddon, B.; Legname, G.; Tomlinson, P.; Zamoyska, R. : Long-term survival but impaired homeostatic proliferation of naive T cells in the absence of p56(lck). Science 290: 127-131 , 2000). Therefore a Lck inhibitor has a high possible therapeutic potential in the treatment of T-cell mediated diseases, e.g. in the treatment of immunologic diseases. Certain autoimmune diseases such as inflammatory diseases (for example inflammatory bowel disease, rheumatoid arthritis, glomerulonephritis and lung fibrosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma, multiple sclerosis and type 1 diabetes are believed to be associated with inappropriate T cell activation (J. H. Hanke et al., Inflamm. Res., 1995, 357). In addition the acute rejection of transplanted organs as well as Graft versus Host Disease (GvHD) after allogeneic bone marrow and stem cell transplantation can also be interpreted as consequence of inappropriate T cell activation. Lck inhibitors offer an approach for treatment of the indications mentioned hereinbefore. Agents of this kind would offer therapy for transplant rejection and autoimmune diseases whilst avoiding toxicities associated with the commonly used, less selective immunosuppressants. The leading agent for prevention or treatment of transplant rejection is cyclosporin A which, although effective, is often associated with side-effects such as renal damage and hypertension which results in kidney failure in a substantial number of patients. It is contemporary practice to treat rheumatoid arthritis initially with symptom relief agents such as NSAIDs, which have no effect on disease progression and are often associated with unwanted side-effects. A rationally based, disease modifying agent, without such deleterious side-effects, would therefore offer significant benefits in the prevention or treatment of transplant rejection or autoimmune conditions such as rheumatoid arthritis.
There is considerable evidence that VEGF plays a key role in the pathogegenesis in rheumatoid arthritis, especially in the formation of the pannus (Paleolog EM, Arthritis Res 2002;4 Suppl 3:S81-90, Pavonen et al, J Rheumatol 2002 Jan;29(1):39-45, Afuwape AO et al, Histol Histopathol 2002;17(3):961-72). Thus, combined inhibition of VEGFR-tyrosine kinases and Lck is considered of potentially high benefit for patients with this disease. The same considerations can be applied to psoriasis and inflammatory bowel disease (Folkman J, Nat Med. 1995 Jan;1 (1):27-31. Review; Griga T et al, Hepatogastroenterology 2002 Jan-Feb;49(43):116-23, Creamer D et al, Arch Dermatol 2002 Jun;138(6):791-6). BRIEF SUMMARY OF THE INVENTION
In view of the work cited above there is a clear need for compounds being active as Lck inhibitors in order to treat T-cell mediated diseases, e.g. in the treatment of immunologic diseases or pathological conditions involving an immunologic component.
It is therefore an object of the invention to provide a method for treating immunologic diseases or pathological conditions involving an immunologic component comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising a compound selected from compounds (A) to (AL) already known as agents for therapy in oncology.
A second object of the invention is a pharmaceutical composition comprising a compound selected from compounds (A) to (AL) together with one or more other drugs selected from nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs), immunsuppressives, biologic response modifiers and antinfectives for use in treatment of immunologic diseases or pathological conditions involving an immunologic component.
A third object of the invention is the use of a compound selected from compounds (A) to (AL) for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
DETAILED DESCRIPTION OF THE INVENTION
It has now surprisingly been found that compounds
(A) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5- (methylsulfonyIamino)-2-indolinone; (B) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5-(ethyl- sulfonylamino)-2-indolinone;
(C) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-5-(ethyl- sulfonylamino)-2-indolinone;
(D) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5- (phenylsulfonylamino)-2-indolinone;
(E) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5-(4- amino-phenylsulfonylamino)-2-indolinone;
(F) (Z)-3-(1 -(4-(pyrrolidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5- (ethylsulfonylamino)-2-indolinone;
(G) (Z)-3-(1-(4-(4-(3-aminopropyl-piperidin-1-yl-methyl)-phenylamino)-1-phenyl- methylene)-5-(ethylsulfonylamino)-2-indolinone;
(H) (Z)-3-(1 -(4-(N-(piperidin-1 -yl-methylcarbonyl)-N-methyl-amino)-phenylamino)- 1-phenyl-methylene)-5-(phenylsulfonylamino)-2-indolinone;
(I) (Z)-3-(1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulfonyl-amino)-phenylamino)- 1-phenyl-methylene)-5-(N-methyl-N-phenylsulfonyl-amino)-2-indolinone;
(J) (Z)-3-(1 -(4-(N-methyl-N-(piperidin-1 -yl-methylcarbonyl)-amino)-phenylamino)- 1-phenyl-methylene)-5-(N-methyl-N-phenylsulfonyl-amino)-2-indolinone;
(K) (Z)-3-(1 -(2-benzimidazoIyl-amino)-1 -phenyl-methylene)-5-amido-2-indolinone;
(L) (Z)-3-(1 -(4-(N-methyl-propionylamino)-phenylamino)-1 -phenyl-methylene)-5- amido-2-indolinone; (M) (Z)-3-(1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulfonyl-amino)-phenylamino)- 1-phenyl-methylene)-2-indolinone;
(N) (Z)-3-(1 -(4-(N-(3-dimethylaminopropyl)-N-propionyl-amino)-phenylamino)-1 - phenyl-methylene)-2-indolinone;
(O) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-5- . (butylcarbamoyl)-2-indolinone;
(P) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5- (naphth-1-yl-methyl-carbamoyl)-2-indolinone;
(Q) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-5-(N- butyl-N-phenyl-carbamoyl)-2-indolinone;
(R) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(hexyl- carbamoyl)-2-indolinone;
(S) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-
(cyclohexylmethyl-carbamoyl)-2-indolinone;
(T) (Z)-3-(1-(4-(N-methylsulfonyl-N-(2-dimethylamino-ethyl)-amino)-phenylamino)- 1-phenyl-methylen)-5-(cyclohexylmethyl-carbamoyl)-2-indolinone;
(U) (Z)-3-(1 -(4-(butylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
(V) (Z)-3-(1 -(4-(pyrrolidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone; (W) (Z)-3-(1 -(4-(diethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
(X) (Z)-3-(1 -(4-(diethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(N-(3- chlorobenzyl)-carbamoyl)-2-indolinone;
(Y) (Z)-3-(1 -(4-(diethanolaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(butyl- carbamoyl)-2-indolinone;
(Z) (Z)-3-(1-(4-(dimethylaminomethyl)-phenylamino)-1-phenyl-methylen)-5-(N-(3- chlorobenzyl)-carbamoyl)-2-indolinone;
(AA) (Z)-3-(1 -(4-(N-acetyl-N-(2-dimethylamino-ethyl)-amino)-phenylamino)-1 - phenyl-methylen)-5-(N-(3-chlorobenzyl)-carbamoyl)-2-indolinone;
(AB) (Z)-3-(1 -(4-(butylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(N-(3- chlorobenzyl)-carbamoyl)-2-indolinone;
(AC) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5-(N- methyl-N-phenyl-aminosulfonyl)-2-indolinone;
(AD) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyI-methylene)-5-(N- butyl-N-methyl-aminosulfonyl)-2-indolinone ;
(AE) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-6- methoxycarbonyl-2-indolinone;
(AF) (Z)-3-(1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-phenylamino)-1- phenyl-methylene)-6-methoxycarbonyl-2-indolinone;
(AG) (Z)-3-(1 -(4-(ethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-6- methoxycarbonyl-2-indolinone; (AH) (Z)-3-(1 -(4-(1 -methyl-imidazol-2-yl)-phenylamino)-1 -phenyl-methylene)-6- methoxycarbonyl-2-indolinone;
(Al) (Z)-3-(1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methyl-amino)-phenylamino)- 1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone;
(AJ) (Z)-3-(1 -(4-(methylaminomethyl)-anilino)-1 -phenyl-methylene)-6-methoxycar- bonyl-2-indolinone;
(AK) (Z)-3-(1 -(4-(N-((4-methyl-piperazin-1 -yl)-methylcarbonyl)-N-methyl-amino)- phenylamino)-1 -phenyl-methylene]-6-methoxycarbonyl-2-indoIinone; and ,
(AL) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)- quinazoline
the tautomers, the stereoisomers and the physiologically acceptable salts thereof,
are effective inhibitors of Lck and therefore are especially suitable and effective in the treatment of immunologic diseases or pathological conditions involving an immunologic component.
Compounds (A) to (J) are described in WO 02/36564, compounds (K) to (L) are described in WO 99/52869, compounds (M) to (N) are described in WO 00/18734, compounds (O) to (AB) are described in WO 00/73297, compounds (AC) to (AD) are described in WO 01/27080, compounds (AE) to (AK) are described in WO 01/27081 , compound (AL) is described in WO 01/32651.
Viewed from a first aspect the present invention provides a method for treating immunologic diseases or pathological conditions involving an immunologic component comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising a compound selected from compounds (A) to (AL), the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.
The expression "patient" is meant to comprise the human and the non-human mammal patient.
The indication "immunologic diseases or pathological conditions involving an immunologic component" should be understood in a non-limiting manner to comprise
autoimmune diseases, for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from
inflammatory bowel disease (e.g. colitis ulcerosa and Morbus Crohn), rheumatoid arthritis, glomerulonephritis and lung fibrosis,
furthermore, psoriasis, psoriasis arthritis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes,
and indications which need immunosuppressant therapy, for instance prevention or therapy of tissue or organ transplant rejection, e.g. acute or chronic graft-versus-host disease, allograft or xenograft rejection etc. The transplanted organ may be kidney, heart, liver, lung, bone marrow, peripheral blood stem cells, pancreas or islet cells thereof, cornea, small bowel, skin, or heart valve.
Preferred indications which may be treated by the method according to the invention are
rheumatoid arthritis,
inflammatory bowel disease such as colitis ulcerosa and Morbus Crohn, psoriasis, psoriasis arthritis,
prevention or therapy of tissue or organ transplant rejection, acute or chronic graft-versus-host disease, allograft or xenograft rejection,
allergic asthma, multiple sclerosis and type 1 diabetes.
A further subgroup of indications which may be treated by the method according to the invention and deserves special mention comprises morbus crohn, lung fibrosis, psoriasis arthritis, hypersensitivity reactions of the skin, graft-versus-host disease (acute and chronic), asthma, multiple sclerosis and type 1 diabetes.
A preferred embodiment of the method according to the invention comprises administration of a compound selected from compounds
(A), (B), (C), (D), (F), (G), (P), (T), (V), (X), (Z), (AA), (AE), (Al), (AK) and (AL),
the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.
Another preferred embodiment of the method according to the invention comprises administration of a compound selected from the following combined inhibitors of VEGFR-2 and Lck
(M), (N), (O), (S), (T), (U), (V), (W), (X), (Y), (Z), (AA), (AB), (AE), (AF), (AG), (AH), (Al), (AJ), (AK) and (AL),
the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.^ Since VEGF also plays an important pathogenetical role in chronic inflammatory bowel diseases such as colitis ulcerosa and morbus crohn as well as in rheumatoid arthritis, psoriasis and psoriasis arthritis these combined inhibitors of VEGFR-2 and Lck are of special advantage in these most preferred indications.
A further preferred embodiment of the method according to the invention comprises administration of a compound selected from compounds
(AK), (Al) and (AL),
the tautomers, the stereoisomers and the physiologically acceptable salts thereof,
especially preferred is administration of compound (AK).
In the method of treatment according to the invention compounds (A) to (AL) can be administered orally, parenterally, rectally or, with respect to indications involving treatment of the skin such as psoriasis, psoriasis arthritis or hypersensitivity reactions of the skin, also in topical formulations. Oral administration is preferred.
In oral, rectal or topical administration the compounds may be given, if required in divided doses, in a daily dosage of 0.1 to 20 mg/kg body weight, preferably 0.5 to 20 mg/kg body weight, most preferred 1 to 10 mg/kg body weight. Parenterally the compounds may be administered in lower doses, for instance in a total daily dosage of 0.01 to 5 mg/kg body weight, preferably 0.05 to 2 mg/kg body weight, most preferred 0.1 to 1 mg/kg body weight.
For administration the compounds may be formulated with one or more conventional inert carriers and/or diluents as known in the art, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, lozenges, hard or soft capsules, dispersible powders or granules, syrups or elixirs, injectable solutions, ampoules, aqueous or oily suspensions, emulsions, solutions, sprays, creams, ointments, gels, or suppositories. Suitable galenic formulations are disclosed in the documents cited hereinbefore.
Furthermore, in the method according to the invention a compound selected from compounds (A) to (AL) may be administered in combination, simultaneously or sequentially, with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers, antinfectives and, in case of lung indications, also with bronchodilators.
In particular a compound selected from compounds (A) to (AL) could be used in combination with immunosuppressives in the prevention or treatment of the acute rejection of transplanted organs,
in combination with NSAIDs, steroids, immunosupressives, DMARDs, biologic response modifiers (e.g. Anti-TNF), and antiinfectives for the treatment of inflammatory bowel disease (e.g. colitis ulcerosa and morbus crohn), rheumatoid arthritis and psoriasis, whereby the NSAID-dose can be significantly reduced compared to the normally needed dose to produce a therapeutic effect thus reducing the risk of adverse side-effects from the NSAID such as gastrointestinal effects,
in combination with biologic response modifiers ( e.g. leukotriene antagonists) and bronchodilators for the treatment of asthma,
Suitable NSAIDs for combination treatment are meant to include all COX (cyclooxygenase) inhibitors, e.g.
non-selective COX-inhibitors such as acetylsalicyclic acid, mesalazin, ibuprofen, naproxen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen,
indomethacin, sulindac, tolmetin, zomepirac, nabumetone, diclofenac, fenclofenac, alclofenac, bromfenac, ibufenac, aceclofenac, acemetacin, fentiazac, clidanac, etodolac, oxpinac,
mefenamic acid, meclofenamic acid, flufenamic acid, nifluminic acid, tolfenamic acid, diflunisal, flufenisal, piroxicam, tenoxicam, lornoxicam and nimesulide and the pharmaceutically acceptable salts thereof,
as well as selective COX 2-inhibitors such as meloxicam, celecoxib and rofecoxib and the pharmaceutically acceptable salts thereof.
Suitable steroids for combination treatment are meant to include in a non-limiting manner prednisone, prednisolone, methylprednisolone, dexamethasone, budenoside, fluocortolone and triamcinolone.
Suitable DMARDs for combination treatment are meant to include in a non-limiting manner sulfasalazine, olsalazine, chloroquin, gold derivatives (Auranofin), D- penicillamine and cytostatics such as methotrexate and cyclophosphamide.
Suitable immunsuppressives for combination treatment are meant to include in a non-limiting manner cyclosporin A and derivatives thereof, mycophenolatemofetil, FK 506, OKT-3, ATG, 15-desoxyspergualin, mizoribine, misoprostol, rapamycin, reflunomide, azathioprine and NF-Kappa B-inhibitors.
Suitable biologic response modifiers for combination treatment are meant to include in a non-limiting manner interferon beta, anti-TNF-alpha (Etanercept), IL-10, oral and parenteral tolerance induction strategies (orally e.g. with genetically modified enteric bacteria), leukotrien-antagonists, anti-CD3 or anti-CD25. Suitable antinfectives for combination treatment are meant to include in a non-limiting manner metronidazol and chinolone for treatment of chronic inflammatory bowel diseases.
Suitable bronchodilators for combination treatment are meant to include in a non- limiting manner those disclosed under "broncholytics/antiasthmatics" in Rote Liste® 2002, Editio Cantor Verlag Aulendorf, Germany, being herewith incorporated by reference, for instance ipratropiumbromide, oxytropiumbromide, tiotropiumbromide, epinephrinehydrochloride, salbutamole, terbutalinsulfate, fenoterolhydrobromide, salmeterole, formoterole, cromiclinic acid, theophylline derivatives etc.
In such combinations each active ingredient can be administered either in accordance with its usual dosage range or a dose below its usual dosage range. The dosage for the combined NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives is appropriately 1/50 of the lowest dose normally recommended up to 1/1 of the normally recommended dosage, preferably 1/20 to 1/2 and more preferably 1/10 to 1/5. The normally recommended dose for the combined drug should be understood to be the dose disclosed for example in Rote Liste® 2002, Editio Cantor Verlag Aulendorf, Germany, or in Physician's Desk Reference.
It can be expected that combination treatment comprising administration of Lck inhibitors together with a second drug selected from those mentioned hereinbefore may provide synergistic efficacy thus allowing significant dose reduction compared to the normally needed dose to produce a therapeutic effect. This would be especially beneficial with regard to medications having a high risk of adverse side-effects as is the case with non-selective COX inhibitors, cyclosporin A or DMARDs.
Viewed from a second aspect the present invention also relates to pharmaceutical composition comprising (a) a compound selected from compounds (A) to (AL), the tautomers, the stereoisomers and the physiologically acceptable salts thereof,
(b) and one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives,
optionally together with pharmaceutically acceptable diluents and/or carriers, as a combined preparation or a kit of parts containing components (a) and (b) in separate containments for simultaneous, separate or sequential use in treatment of immunologic diseases or pathological conditions involving an immunologic component.
Viewed from a third aspect the present invention provides the use of a compound selected from compounds (A) to (AL), the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, for the manufacture of a pharmaceutical composition for the treatment of a patient suffering from immunologic diseases or pathological conditions involving an immunologic component.
Preferred embodiments of either the composition aspect or the use aspect of the invention with respect to the combined VEGFR-2/Lck component correspond to those mentioned hereinbefore for the method of treatment aspect.
Example 1 : Non-radioactive kinase assay (lck)
Methodology The lck enzyme comprises the entire lck molecule except the first nine amino acids which are replaced by an His-tag for purification purposes. The enzyme is affinity purified.
The assay mix is assembled in a well of a 96-well round bottom microtiter plate and contains 10 μl PBS (either as such or with an inhibitor dissolved at an appropriate concentration), 20 μ\ substrate solution (200 mM Hepes, pH=7,4; 50 mM MgAc2; 1 mM Na3V04; 250 μg/ml poly-Glu-Tyr (Sigma P0275); 200 ng/ml biotinylated peptide (biot-Ala-Glu-Glu-Glu-lle-Tyr-Gly-Glu-Phe-Glu-Ala-Lys-Lys-Lys-Lys) and 20 μ\ of 2,5 ng/c/l enzyme (diluted from affinity purified stock with enzyme dilution buffer, EDB: 20 mM Hepes, pH=7,4, 130 mM NaCI, 0,05% Triton X-100).
The reaction is started by the addition of 50 μ\ 500 μM ATP (in 10 mM MgAc2) and is performed at room temperature. After 30 minutes 50 μl stop solution (20 mM Hepes, pH=7,4;250 mM EDTA) are added and 100 /I of this solution transfered to the well of a streptavidin coated microtiter plate (SA-MTP, Boehringer Mannheim, #1664-760). The solution is incubated for one hour at room temparature and the supernatant discarded. The well is washed twice with 300 μl PBS.
The streptavidin bound biotinylated peptide is incubated for 1 hour at room temperature with 100 μl Eu3+-labelled anti-phosphotyrosine antibody solution (0,3 mg/ml DELFIA-Eu-labelled PT66 (Wallac, AD0041); 50 mM Tris, pH=7,8; 0,05% Tween 20; 0,5% (w7v) BSA (Serva, diagnostic grade) under gentle agitation. The well is washed three times with 1x Delfia wash buffer (Wallac, 1244-114, 25x concentrate, diluted with water) and finally 100 μl Delfia enhancement solution (Wallac, 1244-105) are added. Time resolved fluorescense is measured in a Wallac Victor2 1420 Multilabel Counter, excitation is at 340 nm, emission is measured at 615 nm (delay time 400 μsec, wi ndow ti me 1000 μsec) .
Results
In two independent experiments the IC5oS of compounds (A) to (AL) on the kinase have been determined. The data (mean values) obtained with three representative compounds are summarised in the following table:
Compounds (A) to (AH) and (AJ) inhibit the lck kinase function with an IC5o< 1 μM.

Claims

CLAIMS:
1. A method for treating immunologic diseases or pathological conditions involving an immunologic component comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising a compound selected from
(A) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5- (methylsulfonyIamino)-2-indolinone;
(B) (Z)-3-(1 -(4-(piperidin-1 -y!-methyl)-phenylamino)-1 -phenyl-methylene)-5-(ethyl- sulfonylamino)-2-indolinone;
(C) (Z)-3-(1-(4-(dimethylaminomethyl)-phenylamino)-1-phenyl-methylene)-5-(ethyl- sulfonylamino)-2-indolinone;
(D) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5- (phenylsulfonylamino)-2-indolinone;
(E) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5-(4- amino-phenylsulfonylamino)-2-indolinone;
(F) (Z)-3-(1 -(4-(pyrrolidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5- (ethylsulfonylamino)-2-indolinone;
(G) (Z)-3-(1-(4-(4-(3-aminopropyl-piperidin-1-yl-methyl)-phenylamino)-1-phenyl- methylene)-5-(ethylsulfonylamino)-2-indolinone;
(H) (Z)-3-(1 -(4-(N-(piperidin-1 -yl-methylcarbonyl)-N-methyl-amino)-phenylamino)-
1-phenyl-methylene)-5-(phenylsulfonylamino)-2-indolinone; (I) (Z)-3-(1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulfonyl-amino)-phenylamino)- 1-phenyl-methylene)-5-(N-methyl-N-phenylsulfonyl-amino)-2-indolinone;
(J) (Z)-3-(1 -(4-(N-methyl-N-(piperidin-1 -yl-methylcarbonyl)-amino)-phenylamino)- 1-phenyl-methylene)-5-(N-methyl-N-phenylsulfonyI-amino)-2-indolinone;
(K) (Z)-3-(1 -(2-benzimidazolyl-amino)-1 -phenyl-methylene)-5-amido-2-indolinone;
(L) (Z)-3-(1 -(4-(N-methyl-propionylamino)-phenylamino)-1 -phenyl-methylene)-5- amido-2-indolinone;
(M) (Z)-3-(1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulfonyl-amino)-phenylamino)- 1-phenyl-methylene)-2-indolinone;
(N) (Z)-3-(1 -(4-(N-(3-dimethylaminopropyl)-N-propionyl-amino)-phenylamino)-1 - phenyl-methylene)-2-indolinone;
(O) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-5- (butylcarbamoyl)-2-indolinone;
(P) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5- (naphth-1-yl-methyl-carbamoyl)-2-indolinone;
(Q) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-5-(N- butyl-N-phenyl-carbamoyl)-2-indolinone;
(R) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(hexyl- carbamoyl)-2-indolinone;
(S) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-
(cyclohexylmethyl-carbamoyl)-2-indolinone; (T) (Z)-3-(1-(4-(N-methylsulfonyl-N-(2-dimethylamino-ethyl)-amino)-phenylamino)- 1-phenyl-methylen)-5-(cyclohexylmethyl-carbamoyl)-2-indolinone;
(U) (Z)-3-(1 -(4-(butylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
(V) (Z)-3-(1 -(4-(pyrrolidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
(W) (Z)-3-(1 -(4-(diethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(cyclo- hexylmethyl-carbamoyl)-2-indolinone;
(X) (Z)-3-(1 -(4-(diethylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(N-(3- chlorobenzyl)-carbamoyl)-2-indolinone;
(Y) (Z)-3-(1 -(4-(diethanolaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(butyl- carbamoyl)-2-indolinone;
(Z) (Z)-3-(1 -(4-(dimethyIaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(N-(3- chlorobenzyl)-carbamoyl)-2-indolinone;
(AA) (Z)-3-(1 -(4-(N-acetyl-N-(2-dimethylamino-ethyl)-amino)-phenylamino)-1 - phenyl-methylen)-5-(N-(3-chlorobenzyl)-carbamoyl)-2-indolinone;
(AB) (Z)-3-(1 -(4-(butylaminomethyl)-phenylamino)-1 -phenyl-methylen)-5-(N-(3- chlorobenzyl)-carbamoyl)-2-indolinone;
(AC) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5-(N- methyl-N-phenyl-aminosulfonyl)-2-indolinone;
(AD) (Z)-3-(1 -(4-(piperidin-1 -yl-methyl)-phenylamino)-1 -phenyl-methylene)-5-(N- butyl-N-methyl-aminosulfonyl)-2-indolinone ; (AE) (Z)-3-(1 -(4-(dimethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-6- methoxycarbonyl-2-indolinone;
(AF) (Z)-3-(1 -(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-phenylamino)-1- phenyl-methylene)-6-methoxycarbonyl-2-indolinone;
(AG) (Z)-3-(1 -(4-(ethylaminomethyl)-phenylamino)-1 -phenyl-methylene)-6- methoxycarbonyl-2-indolinone;
(AH) (Z)-3-(1 -(4-(1 -methyl-imidazol-2-yl)-phenylamino)-1 -phenyl-methylene)-6- methoxycarbonyl-2-indolinone;
(Al) (Z)-3-(1 -(4-(N-(dimethylaminomethylcarbonyl)-N-methyl-amino)-phenylamino)- 1 -phenyl-methylene)-6-methoxycarbonyl-2-indolinone;
(AJ) (Z)-3-(1 -(4-(methylaminomethyl)-aniIino)-1 -phenyl-methylene)-6-methoxycar- bonyl-2-indolinone;
(AK) (Z)-3-(1 -(4-(N-((4-methyI-piperazin-1 -yl)-methylcarbonyl)-N-methyl-amino)- phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone; and
(AL) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)- quinazoline
the tautomers, the stereoisomers and the physiologically acceptable salts thereof,
optionally in combination with one or more other drugs selected from nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs), immunsuppressives, biologic response modifiers and antinfectives.
2. The method of claim 1 , wherein the immunologic disease or pathological condition involving an immunologic component is selected from
autoimmune diseases, for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from
inflammatory bowel disease (e.g. colitis ulcerosa and Morbus Crohn), rheumatoid arthritis, glomerulonephritisand lung fibrosis,
furthermore, psoriasis, psoriasis arthritis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes,
and indications which need immunosuppressant therapy, for instance prevention or therapy of tissue or organ transplant rejection.
3. The method of claim 2, wherein the immunologic disease or pathological condition involving an immunologic component is selected from
rheumatoid arthritis,
inflammatory bowel disease such as colitis ulcerosa and Morbus Crohn,
psoriasis, psoriasis arthritis,
prevention or therapy of tissue or organ transplant rejection, acute or chronic graft-versus-host disease, allograft or xenograft rejection,
allergic asthma, multiple sclerosis and type 1 diabetes.
4. The method of claim 2, wherein the immunologic disease or pathological condition involving an immunologic component is selected from morbus crohn, lung fibrosis, psoriasis arthritis, hypersensitivity reactions of the skin, graft-versus-host disease (acute and chronic), asthma, multiple sclerosis and type 1 diabetes.
5. The method of claim 2, wherein the immunologic disease or pathological condition involving an immunologic component is selected from chronic inflammatory bowel diseases, such as colitis ulcerosa and morbus crohn, from rheumatoid arthritis, psoriasis and psoriasis arthritis.
6. The method according to any of claims 1 to 5, which method comprises administration of a compound selected from
(A), (B), (C), (D), (F), (G), (P), (T), (V), (X), (Z), (AA), (AE), (Al), (AK) and (AL),
the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.
7. The method of claim 5, which method comprises administration of a compound selected from
(M), (N), (O), (S), (T), (U), (V), (W), (X), (Y), (Z), (AA), (AB), (AE), (AF), (AG), (AH), (Al), (AJ), (AK) and (AL),
the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives.
8. The method according to any of claims 1 to 5, which method comprises administration of a compound selected from (AK), (Al) and (AL) mentioned in claim 1 , the tautomers, the stereoisomers and the physiologically acceptable salts thereof.
9. The method according to any of claims 1 to 8, wherein the compounds are administered orally, parenterally, rectally or, with respect to indications involving treatment of the skin such as psoriasis, psoriasis arthritis or hypersensitivity reactions of the skin, also topically.
10. The method of claim 9, wherein in oral, rectal or topical administration the compounds are given in a daily dosage of 0.1 to 20 mg/kg body weight or in parenteral administration in a total daily dosage of 0.01 to 5 mg/kg body weight.
11. A pharmaceutical composition comprising
(a) a compound selected from compounds (A) to (AL) of claim 1 , the tautomers, the stereoisomers and the physiologically acceptable salts thereof,
(b) and one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives,
optionally together with pharmaceutically acceptable diluents and/or carriers, as a combined preparation or a kit of parts containing components (a) and (b) in separate containments for simultaneous, separate or sequential use in treatment of immunologic diseases or pathological conditions involving an immunologic component.
12. The composition of claim 11 , wherein the NSAID is a non-selective COX-inhibitor or a COX-2 selective inhibitor.
13. The composition of claim 11 , wherein the NSAID is selected from
acetylsalicyclic acid, mesalazin, ibuprofen, naproxen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen,
indomethacin, sulindac, tolmetin, zomepirac, nabumetone, diclofenac, fenclofenac, alclofenac, bromfenac, ibufenac, aceclofenac, acemetacin, fentiazac, clidanac, etodolac, oxpinac,
mefenamic acid, meclofenamic acid, flufenamic acid, nifluminic acid, tolfenamic acid, diflunisal, flufenisal, piroxicam, tenoxicam, lornoxicam, nimesulide,
meloxicam, celecoxib and rofecoxib,
and the pharmaceutically acceptable salts thereof.
14. The composition of claim 11 , wherein the steroid is selected from
prednisone, prednisolone, methylprednisolone, dexamethasone, budenoside, fluocortolone and triamcinolone.
15. The composition of claim 11 , wherein the DMARD is selected from sulfasalazine, olsalazine, chloroquin, gold derivatives (Auranofin), D-penicillamine and cytostatics such as methotrexate and cyclophosphamide.
16. The composition of claim 11 , wherein the immunsuppressive is selected from cyclosporin A and derivatives thereof, mycophenolatemofetil, FK 506, OKT-3, ATG, 15-desoxyspergualin, mizoribine, misoprostol, rapamycin, reflunomide, azathioprine and NF-Kappa B-inhibitors.
17. The composition of claim 11 , wherein the biologic response modifier is selected from interferon beta, anti-TNF-alpha (Etanercept), IL-10, oral and parenteral tolerance induction strategies, leukotrien-antagonists, anti-CD3 and anti-CD25.
18. The composition of claim 11 , wherein the antinfective is selected' from metronidazol and chinolone.
19. The composition of claim 1 1 , wherein the bronchodilator is selected from ipratropiumbromide, oxytropiumbromide, tiotropiumbromide, epinephrinehydro- chloride, salbutamole, terbutalinsulfate, fenoterolhydrobromide, salmeterole, formo- terole, cromiclinic acid, theophylline derivatives.
20. Use of a compound selected from effective compounds (A) to (AL) mentioned in claim 1 , the tautomers, the stereoisomers and the physiologically acceptable salts thereof, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, for the manufacture of a pharmaceutical composition for the treatment of a patient suffering from immunologic diseases or pathological conditions involving an immunologic component.
21. The use of claim 20, wherein the immunologic disease or pathological condition involving an immunologic component is selected from
autoimmune diseases, for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from
inflammatory bowel disease (e.g. colitis ulcerosa and Morbus Crohn), rheumatoid arthritis, glomerulonephritisand lung fibrosis,
furthermore, psoriasis, psoriasis arthritis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes,
and indications which need immunosuppressant therapy, for instance prevention or therapy of tissue or organ transplant rejection.
22. The use of claim 20, wherein the immunologic disease or pathological condition involving an immunologic component is selected from
rheumatoid arthritis,
inflammatory bowel disease such as colitis ulcerosa and Morbus Crohn,
psoriasis, psoriasis arthritis,
prevention or therapy of tissue or organ transplant rejection, acute or chronic graft-versus-host disease, allograft or xenograft rejection,
allergic asthma, multiple sclerosis and type 1 diabetes.
23. The use of claim 20, wherein the immunologic disease or pathological condition involving an immunologic component is selected from morbus crohn, lung fibrosis, psoriasis arthritis, hypersensitivity reactions of the skin, graft-versus-host disease (acute and chronic), asthma, multiple sclerosis and type 1 diabetes.
24. The use of claim 20, wherein the immunologic disease or pathological condition involving an immunologic component is selected from chronic inflammatory bowel diseases, such as colitis ulcerosa and morbus crohn, from rheumatoid arthritis, psoriasis and psoriasis arthritis.
25. The use of claim 20, wherein the compound is selected from the following combined inhibitors of VEGFR-2 und Lck
(M), (N), (O), (S), (T), (U), (V), (W), (X), (Y), (Z), (AA), (AB), (AE), (AF), (AG), (AH), (Al), (AJ), (AK) and(AL) mentioned in claim 1 ,
the tautomers, the stereoisomers and the physiologically acceptable salts thereof, and wherein the indication to be treated is selected from chronic inflammatory bowel diseases, such as colitis ulcerosa and morbus crohn, from rheumatoid arthritis, psoriasis and psoriasis arthritis.
26. The use of a compound selected from
(A), (B), (C), (D), (F), (G), (P), (T), (V), (X), (Z), (AA), (AE), (Al) and (AL) mentioned in claim 1 ,
the tautomers, the stereoisomers and the physiologically acceptable salts thereof,
optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives,
according to any of claims 20 to 24.
27. The use of a compound selected from (AK), (Al) and (AL) mentioned in claim 1 , the tautomers, the stereoisomers and the physiologically acceptable salts thereof, according to any of claims 20 to 24.
28. The use according to any of claims 20 to 25 for the manufacture of a pharmaceutical composition adapted for oral, parenteral, rectal or topical administration.
29. The use of claim 26, wherein the pharmaceutical composition for oral, rectal or topical administration is adapted for administration of a daily dosage of the effective compound of 0.1 to 20 mg/kg body weight or, for parenteral administration, is adapted for a total daily dosage of 0.01 to 5 mg/kg body weight.
EP03792292.9A 2002-08-16 2003-08-11 Use of Nintedanib for the treatment of lung fibrosis Expired - Lifetime EP1530466B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200332413T SI1530466T1 (en) 2002-08-16 2003-08-11 Use of Nintedanib for the treatment of lung fibrosis
EP10184940A EP2281561A3 (en) 2002-08-16 2003-08-11 Use of LCK inhibitors for treatment of immunologic diseases
CY20151100238T CY1116093T1 (en) 2002-08-16 2015-03-09 USE OF NINDENTANIBIS FOR THE PREVENTION OF PULMONARY Fibrosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10237423 2002-08-16
DE10237423A DE10237423A1 (en) 2002-08-16 2002-08-16 Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
PCT/EP2003/008890 WO2004017948A2 (en) 2002-08-16 2003-08-11 Use of lck inhibitor for treatment of immunologic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10184940A Division-Into EP2281561A3 (en) 2002-08-16 2003-08-11 Use of LCK inhibitors for treatment of immunologic diseases

Publications (2)

Publication Number Publication Date
EP1530466A2 true EP1530466A2 (en) 2005-05-18
EP1530466B1 EP1530466B1 (en) 2014-12-10

Family

ID=30469754

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10184940A Withdrawn EP2281561A3 (en) 2002-08-16 2003-08-11 Use of LCK inhibitors for treatment of immunologic diseases
EP03792292.9A Expired - Lifetime EP1530466B1 (en) 2002-08-16 2003-08-11 Use of Nintedanib for the treatment of lung fibrosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10184940A Withdrawn EP2281561A3 (en) 2002-08-16 2003-08-11 Use of LCK inhibitors for treatment of immunologic diseases

Country Status (11)

Country Link
EP (2) EP2281561A3 (en)
JP (1) JP2006514611A (en)
AU (1) AU2003255413A1 (en)
CA (1) CA2495350C (en)
CY (1) CY1116093T1 (en)
DE (1) DE10237423A1 (en)
DK (1) DK1530466T3 (en)
ES (1) ES2530392T3 (en)
PT (1) PT1530466E (en)
SI (1) SI1530466T1 (en)
WO (1) WO2004017948A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154939A1 (en) * 2004-12-24 2006-07-13 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
PE20060777A1 (en) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
FR2909876A1 (en) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Use of 2-(2-amino-3-benzoyl-phenyl)-acetamide and its derivatives for the preparation of a composition for the treatment of skin diseases e.g. rosacea, psoriasis or atopic dermatitis
EP2614832B1 (en) 2007-02-12 2016-07-13 A1M Pharma AB Diagnosis and treatment of preeclampsia
DK2293795T3 (en) * 2008-06-06 2015-10-19 Boehringer Ingelheim Int Pharmaceutical combination.
CA2730531A1 (en) 2008-07-18 2010-01-21 Bo Akerstroem Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP2837626A1 (en) * 2013-08-16 2015-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Indolinone derivatives as GRK5 modulators
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
JP2019511547A (en) 2016-04-13 2019-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
EP3464240A1 (en) 2016-05-27 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
JP2019523225A (en) 2016-06-01 2019-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of ECM biomarkers to determine initiation of treatment with nintedanib and pirfenidone
CN110573161A (en) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 Nintedanib for use in a method of treating muscular dystrophy
BR112020021412A8 (en) 2018-04-23 2022-07-05 Taiwan Liposome Co Ltd PROLONGED RELEASE, INALABLES LIPOSOMAL COMPOSITION FOR USE IN THE TREATMENT OF LUNG DISEASES
CN111285872B (en) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 Indole-2-ketone derivative and preparation method and application thereof
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892248A (en) * 1994-09-26 1996-04-09 Yamanouchi Pharmaceut Co Ltd Indolinone derivative
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
AU751188C (en) * 1997-05-28 2005-06-30 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
YU21301A (en) * 1998-09-25 2003-04-30 Boehringer Ingelheim Pharama Gmbh. & Co. Kg. Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
DE19924401A1 (en) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
EP1222187B1 (en) * 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE19949209A1 (en) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma 5-substituted indolinones, their preparation and their use as pharmaceuticals
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
UA72946C2 (en) 1999-11-05 2005-05-16 Астразенека Аб Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf)
CZ20021703A3 (en) * 1999-11-30 2003-06-18 Pfizer Products Inc. 2,4-Diaminopyrimidine compounds usable as immunosuppressants
AR035851A1 (en) * 2000-03-28 2004-07-21 Wyeth Corp 3-CIANOQUINOLINS, 3-CIANO-1,6-NAFTIRIDINES AND 3-CIANO-1,7-NAFTIRIDINS AS INHIBITORS OF PROTEIN KINASES
DE10054019A1 (en) * 2000-11-01 2002-05-23 Boehringer Ingelheim Pharma New substituted indolinones, their production and their use as medicines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004017948A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
EP2281561A3 (en) 2012-05-09
CY1116093T1 (en) 2017-02-08
DK1530466T3 (en) 2015-03-16
AU2003255413A8 (en) 2004-03-11
CA2495350A1 (en) 2004-03-04
CA2495350C (en) 2012-05-29
ES2530392T3 (en) 2015-03-02
EP2281561A2 (en) 2011-02-09
DE10237423A1 (en) 2004-02-19
AU2003255413A1 (en) 2004-03-11
WO2004017948A8 (en) 2005-03-24
SI1530466T1 (en) 2015-03-31
EP1530466B1 (en) 2014-12-10
WO2004017948A3 (en) 2004-04-22
WO2004017948A2 (en) 2004-03-04
JP2006514611A (en) 2006-05-11
PT1530466E (en) 2015-02-24

Similar Documents

Publication Publication Date Title
US7989474B2 (en) Use of Lck inhibitors for treatment of immunologic diseases
CA2495350C (en) Use of lck inhibitor for treatment of immunologic diseases
JP5964821B2 (en) Treatment of gout and hyperuricemia
US8877764B2 (en) Method for treating cancer harboring EGFR mutations
JP5117189B2 (en) Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases
CA2794798C (en) Treatment of gout
US20110046119A1 (en) Therapeutic treatment
JP2005527523A (en) 4- (4-Methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-yl-amino] phenyl] for treating AngII-mediated diseases -Benzamide
CN103638028A (en) Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
US20080234285A1 (en) Combination of Organic Compounds
JP2009500414A (en) Combination of organic compounds
JP5446271B2 (en) Use of adenine-derived compounds for lupus treatment
KR20220168172A (en) A pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid
MXPA06008295A (en) Combination of organic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050316

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090603

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 60347100

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031404000

Ipc: A61K0031496000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/496 20060101AFI20140626BHEP

Ipc: A61P 11/00 20060101ALI20140626BHEP

Ipc: A61K 45/06 20060101ALI20140626BHEP

INTG Intention to grant announced

Effective date: 20140725

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 700294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60347100

Country of ref document: DE

Effective date: 20150122

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150217

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2530392

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150302

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150309

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E010240

Country of ref document: EE

Effective date: 20150304

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150400445

Country of ref document: GR

Effective date: 20150318

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 18179

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E023598

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60347100

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150911

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 700294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141210

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20220822

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220804

Year of fee payment: 20

Ref country code: SK

Payment date: 20220810

Year of fee payment: 20

Ref country code: SE

Payment date: 20220819

Year of fee payment: 20

Ref country code: RO

Payment date: 20220801

Year of fee payment: 20

Ref country code: PT

Payment date: 20220728

Year of fee payment: 20

Ref country code: LU

Payment date: 20220823

Year of fee payment: 20

Ref country code: IT

Payment date: 20220825

Year of fee payment: 20

Ref country code: IE

Payment date: 20220825

Year of fee payment: 20

Ref country code: GB

Payment date: 20220823

Year of fee payment: 20

Ref country code: FI

Payment date: 20220822

Year of fee payment: 20

Ref country code: EE

Payment date: 20220823

Year of fee payment: 20

Ref country code: DK

Payment date: 20220824

Year of fee payment: 20

Ref country code: DE

Payment date: 20220620

Year of fee payment: 20

Ref country code: CZ

Payment date: 20220811

Year of fee payment: 20

Ref country code: BG

Payment date: 20220823

Year of fee payment: 20

Ref country code: AT

Payment date: 20220822

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20220728

Year of fee payment: 20

Ref country code: MC

Payment date: 20220823

Year of fee payment: 20

Ref country code: HU

Payment date: 20220819

Year of fee payment: 20

Ref country code: GR

Payment date: 20220823

Year of fee payment: 20

Ref country code: FR

Payment date: 20220823

Year of fee payment: 20

Ref country code: BE

Payment date: 20220819

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220824

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20221024

Year of fee payment: 20

Ref country code: CY

Payment date: 20220808

Year of fee payment: 20

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230508

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60347100

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20230811

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20230810

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230825

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230810

REG Reference to a national code

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 18179

Country of ref document: SK

Expiry date: 20230811

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20230811

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 700294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230823

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230811

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230810

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230812

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230811

Ref country code: SI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230812